Results 41 to 50 of about 43,902 (289)

Denosumab treatment in patients with different courses of osteoporosis

Остеопороз и остеопатии, 2017
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with different courses of osteoporosis: postmenopausal with bisphosphonates ineffectiveness, osteoporosis of mixed etiology in patient on thyroid stimulating ...
Liudmila Ya. Rozhinskaya, Elizaveta O. Mamedova, Alexander S. Lutsenko, Anastasia A. Malygina, Zhanna E. Belaya   +4 more
doaj   +1 more source

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation

Frontiers in Endocrinology, 2020
Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless ...
Katharina Jähn-Rickert, Eva M. Wölfel, Björn Jobke, Christoph Riedel, Maya Hellmich, Mathias Werner, Michelle M. McDonald, Björn Busse   +7 more
doaj   +1 more source

Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study [PDF]

, 2018
ObjectivesTo investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment.Design and settingThis retrospective cohort study examines publicly ...
Bero, Lisa, Fabbri, Alice, Grundy, Quinn, Mintzes, Barbara, Moynihan, Ray, Swandari, Swestika   +5 more
core   +1 more source

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

Journal of Clinical Endocrinology and Metabolism, 2020
CONTEXT Denosumab discontinuation is characterized by an increase in bone turnover overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral fractures (VFx) in some patients.
E. Tsourdi, M. Zillikens, C. Meier, J. Body, Elena Gonzalez Rodriguez, A. Anastasilakis, B. Abrahamsen, B. Abrahamsen, E. McCloskey, L. Hofbauer, N. Guañabens, B. Obermayer-Pietsch, S. Ralston, R. Eastell, J. Pepe, A. Palermo, B. Langdahl   +16 more
semanticscholar   +1 more source

Cellular and molecular mediators of bone metastatic lesions [PDF]

, 2018
Bone is the preferential site of metastasis for breast and prostate tumor. Cancer cells establish a tight relationship with the host tissue, secreting factors that stimulate or inhibit bone cells, receiving signals generated from the bone remodeling ...
Battafarano, Giulia, Del Fattore, Andrea, Marampon, Francesco, Rossi, Michela   +3 more
core   +2 more sources

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study

Osteoporosis International, 2023
Summary This registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates. Denosumab was associated with significantly greater risk reduction than alendronate or ibandronate for ...
J. Everts-Graber, H. Bonel, Daniel Lehmann, B. Gahl, H. Häuselmann, U. Studer, H. Ziswiler, S. Reichenbach, Thomas Lehmann   +8 more
semanticscholar   +1 more source

Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]

, 2018
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley, Bone, Cosman, Cummings, Harrington, Heiss, Langdahl, Leder, Li, Li, McClung, Ominsky, Padhi, Papapoulos, Recknor, Saag, van Bezooijen, Wasnich   +17 more
core   +2 more sources

Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis

Circulation, 2021
Supplemental Digital Content is available in the text. Background: Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic ...
T. Pawade, M. Doris, R. Bing, A. White, Laura Forsyth, E. Evans, C. Graham, M. Williams, E. V. van Beek, A. Fletcher, P. Adamson, J. Andrews, T. Cartlidge, W. Jenkins, M. Syed, T. Fujisawa, C. Lucatelli, W. Fraser, S. Ralston, N. Boon, B. Prendergast, D. Newby, M. Dweck   +22 more
semanticscholar   +1 more source

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone [PDF]

, 2016
Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT.
Angelo Paolo Dei Tos, Axel LeCesne, Czar Louie Gaston, David M. Thomas, Giacomo G. Baldi, Hans Gelderblom, Jean-Yves Blay, Michael Parry, Paolo Casali, Piotr Rutkowski, Robert J. Grimer, Robin L. Jones, Sander P. D. Dijkstra, Sant Chawla, Silvia Stacchiotti, Stefano Ferrari   +15 more
core   +1 more source

Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence

Cancers, 2022
Simple Summary The widely accepted local therapy in extremity giant cell tumor of bone (GCTB) is surgery, in the form of extended intralesional curettage with adequate disease clearance and retention of the limb, wherever possible.
A. Borkowska, A. Szumera-Ciećkiewicz, B. Szostakowski, A. Pieńkowski, P. Rutkowski   +4 more
semanticscholar   +1 more source